# Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

> **NCT04690387** · PHASE1 · COMPLETED · sponsor: **Aivita Biomedical, Inc.** · enrollment: 27 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AV-COVID-19
- **OTHER:** GM-CSF

## Key facts

- **NCT ID:** NCT04690387
- **Lead sponsor:** Aivita Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2021-01-13
- **Final completion:** 2021-01-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04690387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04690387, "Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04690387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*